Ser
411 and Akt Ser 473 phosphorylation by Ang II appear to involve EGF receptor transactivation and were inhibited by dominant-negative Ras, whereas the phosphorylation of p70 S6K and ERK but not Akt was sensitive to the MEK inhibitor. By contrast, the phosphorylation of p70 S6K and Akt but not ERK was sensitive to PI3K inhibitors. Similar inhibitory pattern on these phosphorylation sites by EGF but not insulin was observed. Taken together with the inhibition of Ang II-induced p70 S6K activation by dominant-negative Ras and the MEK inhibitor, we conclude that Ang II-initiated activation of p70 S6K requires both ERK cascade and PI3K/Akt cascade that bifurcate at the point of EGF receptor-dependent Ras activation.
The ubiquitous mitogen-activated Ser/Thr kinase, p70 ribosomal protein S6 kinase (p70 S6K ) participates in the translation of mRNAs, which contain an oligopyrimidine tract at their transcriptional start site. This family of mRNAs encode many of the components of the translational apparatus, including ribosomal proteins and elongation factors. Thus, activation of p70 S6K has long been thought to be a prerequisite to protein synthesis. Inhibition of the kinase activation suppresses cell growth and in some cell types blocks cell cycle progression (1) (2) (3) .
Activation of p70 S6K appears to involve multiple signal inputs. The immunosuppressant rapamycin is the most potent inhibitor of p70 S6K described, blocking its activation by all known agents (1) . It forms a gain-of-function inhibitory complex with FKBP12 that targets mTOR, a member of the phosphatidylinositol 3-kinase (PI3K) 1 -related family of protein kinases (4) . Because an mTOR mutant, which is unable to bind rapamycin-FKBP12, protects p70 S6K activity in the presence of the inhibitor, it has been reasoned that mTOR is an upstream regulator of p70 S6K (5) . PI3K has also been implicated in the signal transduction of p70 S6K activation (6) . Constitutively active PI3K alleles cause elevations in p70 S6K activity, and the inhibitors of PI3K, wortmannin and LY294002, inhibit the activation of p70 S6K by various agonists (1) (2) (3) . The downstream effector of PI3K, Akt/ protein kinase B (PKB) mediates PI3K-dependent p70 S6K activation. Oncogenic or membrane-targeted mutants of Akt activate p70 S6K , which is blocked by rapamycin (7, 8) . Recently, phosphorylation and activation of mTOR by Akt was reported (9) .
Although mitogens that activate p70 S6K simultaneously activate extracellular signal-regulated kinase (ERK/MAPK), p70 S6K and the Ras/ERK cascade have since been shown to lie on distinct pathways (6, 10 -12) . Rapamycin inactivates p70 S6K without having any discernible effects on ERK (6) . A Ras mutant blocks activation of ERK but not p70 S6K . Certain PDGF receptor mutants, which normally activate Ras, fail to activate p70 S6K (11) . However, a recent study showed that a conditionally active Raf-1 mutant as well as a constitutively active MEK1 activates p70 S6K in CCL39 fibroblasts (13) . Beside the ERK cascade, the small G proteins, Cdc42 and Rac1 (14) , and both conventional (6) and atypical (15) PKCs are also implicated in p70 S6K activation. Along with the diversity in the activating pathways, a complex multisite phosphorylation, directed to different domains, are required for p70 S6K activation (2, 3) . Phosphorylation of closely clustered Ser 411 , Ser 418 , Thr 421 , and Ser 424 , located within a pseudosubstrate autoinhibitory domain, is not sufficient for the kinase activation but seems to be a prerequisite for its activation (2, 3) . Although each of these Ser/Thr residues are followed immediately by a proline residue and can be phosphorylated in vitro by an array of prolinedirected kinases including ERK (16) by mTOR has recently been demonstrated (19) . Taken together, it now appears likely that p70 S6K activation requires a complex array of separate, concurrent phosphorylations at multiple sites catalyzed by several protein kinases. However, the precise mechanism of activation as well as the identity of the p70 S6K kinases are yet largely unclear. Recently, rapid activation of p70 S6K has been reported in rat balloon-injured arteries (20) and pressure-overloaded hearts (21) , suggesting the significance of p70 S6K as a potential therapeutic target in cardiovascular diseases. Angiotensin II (Ang II), a major effector peptide of the renin-angiotensin system, is now widely believed to play a critical role in vascular remodeling associated with hypertension, atherosclerosis, and restenosis after vascular injury (22) . We and others have previously cloned the Ang II type 1 receptor (AT 1 ), a heterotrimeric G protein-coupled receptor (GPCR) (23, 24) that not only mediates diverse hemodynamic effects of Ang II but also promotes hypertrophy and/or hyperplasia of vascular smooth muscle cells (VSMC) (25, 26) . In VSMC, Gq-coupled AT 1 activates phospholipase C, which initiates the generation of inositol trisphosphate and diacylglycerol, causing intracellular Ca 2ϩ mobilization and PKC activation, respectively (25) . Moreover, Ang II induces several signaling events commonly evoked by growth factor receptors, such as protein tyrosine phosphorylation and activation of ERK in VSMC (25) (26) (27) . Earlier studies from our laboratory indicate that a Ca 2ϩ -dependent tyrosine kinase may mediate Ang II-induced Ras and ERK activation in cultured VSMC (28) . Subsequently, we have shown that this mechanism involves the ligand-independent transactivation of the EGF receptor (EGFR) (29) .
Previous studies demonstrated that Ang II stimulated p70 S6K through AT 1 in cultured VSMC and cardiac myocytes and that rapamycin markedly inhibited Ang II-induced protein synthesis in these cells (30, 31) . Although much progress has recently been achieved to understand the signaling relay from GPCRs to the ERK cascade (32), little is known about the mechanism by which GPCRs activate p70 S6K (33) . Because both ERK and p70 S6K have been implicated in Ang II-induced protein synthesis (30, 34, 35) and an unidentified proline-directed protein kinase such as ERK may be a required link leading to p70 S6K activation through Ser/Thr phosphorylation at its pseudosubstrate domain, the present study was designed to examine possible cross-talk between the ERK cascade and the Cell Culture-VSMC were prepared from the thoracic aorta of Harlan Sprague-Dawley rats by the explant method and cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum as described previously (36) . To make the condition of cells uniform, VSMC from frozen stock were not used. Subcultured VSMC from passages 3-15, used in the experiments, showed Ͼ99% positive immunostaining of smooth muscle ␣-actin antibody. The expression of AT 1 but not AT 2 was confirmed (28) . Cells at ϳ80% confluence in culture wells were made quiescent by incubation with serum-free DMEM for 3 days.
Transfection by a Recombinant Adenovirus-Replication-defective E1 Ϫ and E3 Ϫ adenoviral vectors containing CA promoter comprised of a cytomegalovirus enhancer and a chicken ␤-actin promoter were prepared. Adenoviruses expressing either a dominant-negative mutant of Ha-Ras, in which Asp 57 was replaced by a tyrosyl residue (AdRasY 57 ), or bacterial ␤-galactosidase (AdLacZ) were constructed as described previously (37) . VSMC were incubated in DMEM containing one of the viral constructs (40 moi) for 2 h at room temperature, washed with DMEM, and further incubated for 3 days under serum-free conditions. Virtually all cells were transfected, as we have previously shown (37) .
Immunoblotting-Quiescent VSMC were stimulated with agonists at 37°C in serum-free DMEM for specified durations. The reaction was terminated by the replacement of medium with SDS-polyacrylamide gel electrophoresis buffer containing 2-mercaptoethanol. After brief sonication, samples were boiled and centrifuged, and the supernatant was subjected to SDS-polyacrylamide gel electrophoresis and immunoblotted as described previously (29) .
Measurement of Intracellular Ca 2ϩ -Fura-2 was used to monitor changes in intracellular Ca 2ϩ concentration using a previously described procedure (38) . After incubation in serum-free DMEM for 48 h, cells were trypsinized, incubated with 4 M fura-2 acetoxymethylester for 30 min at 37°C in Krebs-Ringer HEPES solution (20 mM HEPES, pH 7.4, 130 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 1.5 mM CaCl 2 , 10 mM glucose, 0.1% bovine serum albumin), and resuspended to 2 ϫ 10 6 cells/ml. Measurements of fluorescence were made at 37°C using a SPEX dual wavelength fluorometer (excitation at 340 and 380 nm; emission at 510 nm).
Immune Complex p70 S6K Kinase Assay-Quiescent VSMC were stimulated with agonists at 37°C in serum-free DMEM for specified durations. The reaction was terminated by the replacement of medium with ice-cold lysis buffer (10 mM Tris-HCl, pH 7.4, 50 mM NaCl, 50 mM NaF, 30 mM sodium pyrophosphate, 5 mM EGTA, 1 mM Na 3 VO 4 , 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 10 g/ml leupeptin, and 10 g/ml aprotinin). After brief sonication (5 s), the lysates were clarified by centrifugation for 5 min at 14,000 ϫ g and immunoprecipitated with anti-p70 S6K antibody preadsorbed to protein A-agarose beads for 3 h at 4°C. The immune complexes were washed twice with lysis buffer and once with kinase assay buffer (20 mM MOPS, pH 7.2, 25 mM ␤-glycerophosphate, 5 mM EGTA, 1 mM Na 3 VO 4 , 1 mM dithiothreitol). The beads were then resuspended in kinase assay buffer containing 50 M specific S6 kinase substrate AKRRRLSSLRA (Upstate Biotechnology), 15 mM MgCl 2 , 100 M ATP, 5 Ci of ]␥-32 P]ATP (3000 Ci/mmol), and protein kinase inhibitor mixture, which blocks the activity of other Ser/Thr kinases (Upstate Biotechnology; 5 M PKC inhibitor peptide, 0.5 M PKA inhibitor peptide, and 5 M calmodulin dependent kinase inhibitor compound R24571). After incubation for 10 min at 30°C, the reaction mixture was applied onto P-81 phosphocellulose membrane (Whatman) and extensively washed in 1% acetic acid and then in deionized water. The radioactivity trapped on the membrane was measured by liquid scintillation counting. S6K at Ser 411 was first detected at 10 min in 100 nM Ang II, peaked at 20 min, and then declined (Fig. 1A) . The Ser 411 phosphorylation was dependent on the Ang II concentration; marked phosphorylation was observed at a concentration as low as 1 nM and maximal at 10 -100 nM (Fig. 1B) . The amount of p70 S6K remained unchanged during Ang II stimulation. The phosphorylation by Ang II was completely inhibited by the AT 1 antagonist CV11974 (Fig. 1B) , indicating that Ang II-induced Ser 411 phosphorylation of p70 S6K was mediated by AT 1 .
RESULTS

Ang
In VSMC, we have recently shown that AT 1 transactivates EGFR but not PDGFR (29) , whereas earlier studies by others demonstrated that PDGFR is transactivated by Ang II (39) . To clarify the role of these receptor tyrosine kinases in Ang IIinduced p70 S6K activation, we first compared the effects of EGF and PDGF on Ser 411 phosphorylation of p70 S6K with those of Ang II. The time course of the p70 S6K phosphorylation by EGF followed an almost similar time dependence to Ang II, whereas PDGF induced sustained phosphorylation up to 80 min (Fig. 1C) .
To further examine the possible involvement of EGFR in p70 S6K phosphorylation evoked by Ang II, we tested the effect of the selective EGFR kinase inhibitor AG1478 (40) on Ang II-induced Ser 411 phosphorylation of p70 S6K . Pretreatment of VSMC with AG1478 almost completely inhibited the Ang IIinduced p70 S6K phosphorylation (Fig. 2, A and B) . AG1478 also completely blocked EGF-induced Ser 411 phosphorylation without affecting that by PDGF (Fig. 2B) , confirming its stringent kinase selectivity. Consistent with our previous observation that Ang II transactivates EGFR through intracellular Ca 2ϩ elevation, the Ca 2ϩ ionophore A23187 stimulated the p70 S6K phosphorylation, which was also inhibited by AG1478 (Fig. 2B) . Similar inhibitory patterns on ERK phosphorylation at Tyr 204 by these agonists were obtained by AG1478 (Fig. 2B) and ERK cascade have since been believed to lie on distinct pathways (6, 10 -12) , recent studies indicate the presence of signaling cross-talk between these cascades (13) . Thus, requirement of EGFR and intracellular Ca 2ϩ elevation for both the Ang II-induced p70 S6K phosphorylation and ERK activation prompted us to investigate whether the ERK cascade contributes to Ser 411 phosphorylation of p70 S6K by Ang II. First, the effect of the selective MEK inhibitor PD98059 on Ang II-and insulin-induced Ser 411 phosphorylation was examined. By contrast to Ang II, insulin-induced Ser 411 phosphorylation was delayed, and it had little if any effect on ERK1/2 phosphorylation (Fig. 3A) . Interestingly, PD98059 markedly inhibited Ang II-induced Ser 411 phosphorylation of p70 S6K without affecting that by insulin (Fig. 3B) . Dose dependence of the inhibitory effect of PD98059 on Ang II-induced phosphorylation of ERK and p70 S6K appeared to be well correlated (Fig. 3C ). PD98059 also inhibited the EGF-induced phosphorylation of p70 S6K as well as ERK1/2 (Fig. 3D) (Fig. 4B ) by Ang II, whereas the control with AdLacZ transfection had no effect on both of the phosphorylation reactions. Neither AdRasY 57 nor AdLacZ affected the expression of ERK2 and p70 S6K proteins, and transfection efficiency was confirmed by immunoblotting with anti-human Ha-Ras antibody (Fig. 4, A and B) . To support the notion that EGFR mediates the Ang II-induced p70 S6K phosphorylation, AdRasY 57 also inhibited the Ser 411 phosphorylation by EGF (Fig. 4C) . Surprisingly, insulin-induced Ser 411 phosphorylation of p70 S6K was similarly inhibited by the AdRasY 57 transfection (Fig. 4C) . These data indicate the possibility that a Ras effector system other than the Raf/MEK/ERK cascade such as the PI3K cascade may also be involved in Ser 411 phosphorylation of p70 S6K in VSMC.
Roles of PI3K and mTOR in Ang II-induced Ser
411 Phosphorylation of p70
S6K
-To investigate the roles of PI3K and mTOR in Ang II-induced p70 S6K phosphorylation at Ser 411 , the effect of two commonly used PI3K inhibitors, wortmannin and LY294002, and the mTOR inhibitor rapamycin were tested. Pretreatment with these inhibitors almost completely abolished Ang II-induced p70 S6K phosphorylation at Ser 411 , whereas Ang II-induced ERK phosphorylation was not reduced by the inhibitors (Fig. 5) . Also, these two PI3K inhibitors mark- edly inhibited both EGF-and PDGF-induced p70 S6K phosphorylation without affecting their ERK phosphorylation (Fig. 5B) , both of which are required for full kinase activation (41, 42) . To elucidate the involvement of Akt in Ang II-induced p70 S6K activation, the effects of Ang II, insulin, and EGF on Ser 473 phosphorylation of Akt were compared (Fig. 6A) . Ang II-induced Akt phosphorylation was detected within 5 min, reached a maximum at 10 min, and then declined to the basal level at 40 min. Insulin markedly stimulated Akt phosphorylation within 5 min, and it was sustained up to 40 min. EGF also stimulated Akt phosphorylation, which was maximal at 5-10 min (Fig. 6A) . The Ang II-induced phosphorylation of Akt was completely inhibited by CV11974 (Fig.   6B ). A23187 but not phorbol 12-myristate 13-acetate mimicked the phosphorylation by Ang II (Fig. 6C) . These data indicate that G q -coupled AT 1 receptor mediates the Akt activation by Ang II, presumably through intracellular Ca 2ϩ mobilization. To test the involvement of PI3K, mTOR, and EGFR in Ang II-induced Akt phosphorylation, the effects of wortmannin, LY294002, rapamycin, and AG1478 on Ser 473 phosphorylation of Akt were examined. Both wortmannin and LY294002 almost completely inhibited Akt phosphorylation induced by Ang II, A23187 (Fig. 7A) , and EGF (Fig. 7B) , whereas rapamycin had no effect on the phosphorylation by Ang II and A23187 (Fig.  7A) . AG1478 completely inhibited EGF-induced Akt phosphorylation and partially but markedly inhibited the Ang II-and A23187-induced phosphorylation, whereas it had no effect on the insulin-induced phosphorylation (Fig. 7C) . AG1478 also markedly inhibited Ang II-induced Thr 308 phosphorylation of Akt in VSMC (Fig. 7D) . These data suggest that Ang II activates Akt through EGFR-dependent PI3K activation and that this Akt activation is located upstream of mTOR.
To determine whether Akt represents a PI3K inhibitor-sen- sitive and/or Ras-dependent input that contributes to Ang IIinduced p70 S6K Ser 411 phosphorylation in parallel with ERK, the effects of dominant-negative Ras and PD98059 on Ser 473 phosphorylation of Akt were examined. Transfection of AdRasY 57 markedly inhibited the Akt phosphorylation by Ang II and EGF as well as insulin (Fig. 8, A and B) . By contrast, PD98059 had no effect on the Akt phosphorylation by Ang II or EGF (Fig. 8C) . Taking these data together, it is likely that the A, VSMC were pretreated with rapamycin (100 ng/ml), wortmannin (100 nM), or LY294002 (50 M) for 30 min and stimulated with Ang II (100 nM) for indicated durations. B, VSMC were pretreated with wortmannin (100 nM) or LY294002 (50 M) for 30 min and stimulated with Ang II (100 nM), EGF (100 ng/ml), or PDGF-BB (100 ng/ml) for 20 min (top and middle panels) or 10 min (bottom panel). Cell lysates were analyzed by immunoblotting (IB) with antibodies as indicated. DMSO, dimethyl sulfoxide.
FIG. 6. Phosphorylation of Akt/PKB at Ser
473 by Ang II, insulin, EGF, and A23187. A, VSMC were stimulated with Ang II (100 nM), insulin (100 nM), or EGF (100 ng/ml) for indicated durations. B, after pretreatment with or without CV11974 (100 nM) for 30 min, VSMC were stimulated with Ang II (100 nM) for 10 min. C, VSMC were stimulated with A23187 (10 M) or phorbol 12-myristate 13-acetate (100 nM) for indicated durations. Cell lysates were analyzed by immunoblotting (IB) with antibodies as indicated. The arrows indicate the position of Akt.
Ang II-induced p70 S6K phosphorylation requires both ERK and PI3K/Akt cascades that bifurcates at the level of EGFR-dependent Ras activation in VSMC.
Ang II-induced p70 S6K Activation Is Inhibited by AG1478, PD98059, Dominant-negative Ha-Ras, and Wortmannin-Finally, we have investigated whether Ang II-induced EGFR transactivation and subsequent Ras, MEK, and PI3K activation are indeed required for Ang II-induced p70 S6K activation by immune complex kinase assay. The time courses of agonistinduced p70 S6K activation were well correlated with their Ser 411 phosphorylation (Fig. 9A) . AG1478 markedly and PD98059 partially inhibited both Ang II-and EGF-induced p70 S6K activation, whereas these inhibitors had no effect on insulin-induced p70 S6K activation (Fig. 9, B and C) . By contrast, AdRasY 57 but not AdLacZ partially but markedly inhibited p70 S6K activation by Ang II and EGF as well as insulin (Fig. 9D) . Wortmannin also markedly inhibited the activation by Ang II, EGF, and insulin (Fig. 9E) . These data suggest that in addition to the general involvement of Ras and PI3K for p70 S6K activation, Ras-dependent ERK activation operating through the EGFR transactivation may be required for p70 S6K activation by Ang II possibly through its positive input to the Ser 411 kinase of p70 S6K .
DISCUSSION
The major finding of this study is that Ang II-induced p70 S6K activation in VSMC requires two parallel pathways that bifurcate at the point of EGFR-dependent Ras activation. One is the ERK cascade and the other may involve PI3K/Akt/mTOR. These data will provide new insight into the signaling mechanism by which Ang II contributes vascular hypertrophy. Although phosphorylation of the autoinhibitory domain of p70 S6K is not sufficient for the kinase activation, recent studies have shown its ability to gain access of p70 S6K kinases such as PDK1 to sites whose phosphorylation are critical for p70 S6K activation (2, 17, 18, 43, 44) . Using a phospho Ser 411 -specific antibody for p70 S6K , the present study clearly demonstrated that Ang II-induced Ser 411 phosphorylation of p70 S6K was markedly inhibited by selective inhibitors for the signal transduction molecules that had not been implicated in GPCR-induced activation of p70 S6K . Specificities of the phospho-specific antibodies (44, 45) and the inhibitors, AG1478 (40), dominantnegative Ras (37) , and PD98059 (46) used in the present study have been well established in past publications and our previous (28, 29) and present studies. As we demonstrated in VSMC, phosphorylation of the autoinhibitory domain of p70 S6K de- FIG. 7 . Effects of PI3K inhibitors and AG1478 on phosphorylation of Akt/PKB. A and B, VSMC were pretreated with wortmannin (100 nM), LY294002 (50 M), or rapamycin (100 ng/ ml) for 30 min and stimulated with Ang II (100 nM), A23187 (10 M), or EGF (100 ng/ml) for 10 min. C, VSMC were pretreated with or without AG1478 (250 nM) for 30 min and stimulated with Ang II (100 nM), EGF (100 ng/ml), A23187 (10 M), or insulin (100 nM) for 10 min. Cell lysates were analyzed by immunoblotting (IB) with antibodies as indicated. D, VSMC were pretreated with or without AG1478 (250 nM) for 30 min and stimulated with Ang II (100 nM) for 10 min. Cell lysates were immunoprecipitated with anti-Akt antibody and analyzed by immunoblotting with antibodies as indicated.
FIG. 8. Effects of dominant-negative
Ha-Ras and MEK inhibitor on Akt/ PKB phosphorylation. A and B, VSMC were transfected with AdRasY 57 (ϩ) or control AdLacZ (Ϫ) and stimulated with Ang II (100 nM) for 10 min, EGF (100 ng/ml) for 10 min, or insulin (100 nM) for indicated durations. C, VSMC were pretreated with or without the MEK inhibitor PD98059 (25 M) for 60 min and stimulated with Ang II (100 nM) or EGF (100 ng/ml) for 10 min. Cell lysates were analyzed by immunoblotting (IB) with antibodies as indicated. An arrow indicates the position of Akt.
tected by phospho-specific antibodies was a feature commonly shared by GPCRs and growth factor receptors (44, 45) .
Several GPCR agonists have been shown to activate ERK through EGFR transactivation (47) (48) (49) , and elevation of intracellular Ca 2ϩ is a sufficient signal for EGFR transactivation (50) . Recently, we and others have shown that Ang II and bradykinin induce Ca 2ϩ -dependent EGFR transactivation in VSMC (29) and PC12 cells (51) , respectively. The present study further extended this transactivation mechanism to GPCR (AT 1 )-induced Ser 411 phosphorylation and subsequent activation of p70
S6K
. Although earlier studies demonstrated Ang II-induced PDGFR transactivation in VSMC (39), the involvement of PDGFR in Ang II-induced p70 S6K activation is unlikely because Ang II failed to induce tyrosine phosphorylation of PDGFR in our VSMC (29) . Indeed, GPCR-mediated PDGFR transactivation has recently been shown to occur only when the target cell lacks EGFR (52) .
Consistent with our present observation, A23187 has been shown to activate p70 S6K in Swiss 3T3 fibroblasts (53) and Graves et al. (54) have reported that Ang II-induced Ca 2ϩ -dependent p70 S6K activation was completely inhibited by the tyrosine kinase inhibitor genistein in liver epithelial cells. Because AG1478 at a concentration of 250 nM blocks EGF-induced ERK phosphorylation in VSMC (29) and because it did not completely inhibit Ang II-induced p70 S6K activation, other Ca 2ϩ -dependent tyrosine kinase(s) may also contribute to the activation of p70
. Likely candidate(s) mediating the AG1478-insensitive p70 S6K activation could be a novel Ca 2ϩ -dependent tyrosine kinase, Pyk2, and/or c-Src, both of which have also been implicated in GPCR-mediated ERK activation in many cells (55) (56) (57) (58) . In liver epithelial cells, activation of Pyk2 and p70 S6K by Ang II was well correlated (54) . In VSMC, we and others have recently shown that Ang II activates Pyk2 through intracellular Ca 2ϩ release (59 -61) and Pyk2 associates with c-Src (60, 61) . We have further showed that these events were not inhibited by AG1478 (61) . c-Src appeared to function upstream of GPCR-induced EGFR transactivation (29, 49) , and we found that the inducible association of c-Src with EGFR by Ang II was insensitive to AG1478 in VSMC (29) . However, whether signals from these tyrosine kinases are sufficient to the activation of p70 S6K remains to be determined. S6K in response to a G i -coupled -opioid receptor stimulation (45) . In contrast, the present study clearly demonstrates that the G q -coupled AT 1 -induced Ser 411 phosphorylation and subsequent activation of p70 S6K were prevented by PD98059 or the dominant-negative Ras. Consistent with our observation, others have indicated the involvement of a PD98059-sensitive kinase in insulin-induced p70 S6K activation of 3T3-L1 adipocytes and CHO cells in which insulin activates ERK (62) . In CCL39 fibroblasts, conditionally active Raf-1 stimulation resulted in rapid activation of both ERK and p70 S6K (13) . Moreover, ERK2 efficiently phosphorylates a synthetic peptide with the amino acid sequence of the autoinhibitory domain of p70 S6K in vitro (16) .
In addition to ERK, cyclin-dependent kinases, and other members of the MAPK family such as c-Jun N-terminal kinase (JNK) and p38 MAPK are also claimed as the p70 S6K kinases (44) . However, PD98059 dose not interfere with JNK or p38 MAPK both in vitro and in vivo (46) . The effects of Ang II on JNK and p38 MAPK in VSMC are controversial (63) (64) (65) . Although in vivo Ser 411 phosphorylation of p70 S6K by a cyclin-dependent kinase, cdc2, has recently been demonstrated during mitosis in human T cells (66) , the involvement of cyclin-dependent kinases in the Ang II-induced rapid activation of p70 S6K is unlikely. Given these observations, however, it may be premature to conclude that ERK is the in vivo Ser 411 kinase. In view of their extremely restricted substrate specificities, it is unlikely that MEK1 or MEK2 phosphorylates p70
S6K . An earlier study reported that ERK2 failed to directly phosphorylate p70 S6K in vitro (10) . Overexpression of a MAPK phosphatase, MKP-1, had no effect on the Raf-1-induced p70 S6K activation, whereas it markedly reduced the ERK activation in CCL39 cells (13 ERK was not elevated (62) . By contrast, we observed that dose-dependent effects of PD98059 on ERK and p70 S6K were well correlated in Ang II-stimulated VSMC. However, PI3K inhibitors as well as rapamycin inhibited the Ang II-induced phosphorylation of p70 S6K but not ERK in our VSMC. Taken together, we propose that the Ang II-induced Ser 411 kinase activation may require two parallel pathways, both of which bifurcate at the point of EGFR-dependent Ras activation (Fig.  10) ; one is the ERK pathway and the other is the PI3K/Akt pathway as discussed below.
Both PI3K and mTOR are considered to be major positive regulators of p70 S6K (1) (2) (3) (4) (5) (6) . In liver epithelial cells, Ang II-and A23187-induced p70 S6K phosphorylation was inhibited by wortmannin and rapamycin (54) . Recently, Thr 421 /Ser 424 phosphorylation of p70 S6K was shown to be inhibited by these inhibitors in -opioid receptor-stimulated CHO cells (45) and by dominant-negative PI3K in insulin-stimulated 3T3-L1 adipocytes (67) . In the present study, Ser 411 phosphorylation of p70 S6K induced by Ang II as well as growth factors (EGF, PDGF, and insulin) was markedly inhibited by wortmannin, LY294002, and rapamycin, further indicating the general contribution of PI3K and mTOR to the autoinhibitory domain kinase.
One of the effectors of PI3K, Akt/PKB, has recently been implicated in p70 S6K activation (7, 8) . Dominant-negative Akt (68) inhibited insulin-induced p70 S6K activation, and conditionally active Akt rapidly stimulated p70 S6K (69) . A recent study indicates that PI3K activates mTOR through Akt (9) . In the present study, Ang II induced Ser 473 phosphorylation of Akt that was inhibited by wortmannin and LY294002 but not rapamycin. Similar inhibitory patterns by these inhibitors in the phosphorylation of p70 S6K at Thr 421 /Ser 424 and that of Akt at Ser 473 were shown in Gi-coupled -opioid receptor-stimulated CHO cells (45) , suggesting the involvement of Akt in a GPCRinduced p70 S6K activation through mTOR. Moreover, our data indicate that the Ang II-induced Akt phosphorylation is also driven by the Ca 2ϩ -dependent EGFR transactivation, which may recruit and thereby activate PI3K. In line with our observation, AG1478 inhibited lysophosphatidic acid-enhanced PI3K activity associated with Grb2 in COS-7 cells (48), and Ang II elevated PI3K activity through AT 1 in VSMC (70) . More recently, Takahashi et al. (71) reported that Ang II-induced Akt activation was sensitive to the tyrosine kinase inhibitor genistein in VSMC. In contrast, both G q -coupled m1 and G i -coupled m2 receptors transfected in COS-7 cells have been shown to activate Akt through PI3K␥ (72) . However, activation of this class of PI3K by GPCRs through G␤␥ subunits is usually associated with wortmannin-sensitive activation of ERK (72, 73) . In addition, Conus et al. (74) have recently reported that the drugs that elevate intracellular Ca 2ϩ levels activate p70 S6K in a wortmannin-sensitive manner without affecting Akt activity in Balb/c-3T3 fibroblasts. Thus, the mechanism of Akt activation by GPCR agonists appears to be cell type-specific, and the roles of other PI3K effectors such as Rac (75) in Ang II-induced p70 S6K activation remains to be examined. Earlier studies showed that Ras was not necessary for p70 S6K activation in various cells stimulated by PDGF, insulin, and EGF, respectively (11) . Also, Ras was not needed for PDGF-induced Akt activation in Rat-1 cells (7). However, Ras may contribute to GPCR-induced Akt and p70 S6K activation in some cell types where Ras has the ability to activate PI3K (76, 77) . Indeed, the present study indicates that Ras represents a point of signaling convergence by which Ang II stimulates not only ERK but also Akt, thereby positively regulating p70 S6K . In agreement with this conclusion, constitutively active Ras induced wortmannin-and LY294002-sensitive Akt activation, and dominant-negative Ras has been reported to inhibit Akt activation by PDGF, EGF, and insulin (78 -81) . Also, expression of a constitutively active Ras was shown to be sufficient for Akt activation in several cell lines (82) (83) (84) and for p70 S6K activation in MDCK cells (82) .
At present, no experimental data are available to explain why insulin failed to activate ERK, even its activation of Akt and p70 S6K was markedly inhibited by dominant-negative Ras in VSMC. It has recently been demonstrated that Ras isoform vary in their ability to activate Raf-1 and PI3K. Ha-Ras is a more potent activator of PI3K than K-Ras (85). R-Ras has been shown to activate the PI3K/Akt pathway but not the Raf/ERK pathway (80). Thus, it is possible that insulin may activate unique member(s) of the Ras family that preferentially act on PI3K rather than Raf-1 in VSMC.
In summary, our data indicate that in addition to the well known growth factor-stimulated pathway involving PI3K, Akt, and mTOR, Ang II-induced p70 S6K activation requires the transactivation of EGFR and subsequent Ras and ERK activation. Identification of a putative p70 S6K kinase that phosphorylates autoinhibitory domain of p70 S6K in response to these inputs may provide a potential theraptic target whereby various vasculotrophic factors promote abnormal remodeling of the vessel wall. 
